1. Localized multidrug co-delivery by injectable self-crosslinking hydrogel for synergistic combinational chemotherapy
   Mengmeng He et al, 2017, Journal of Materials Chemistry B CrossRef
2. Autophagic cell death associated to Sorafenib in renal cell carcinoma is mediated through Akt inhibition in an ERK1/2 independent fashion
   Leticia Serrano-Oviedo et al, 2018, PLOS ONE CrossRef
3. PADI2‐Catalyzed MEK1 Citrullination Activates ERK1/2 and Promotes IGF2BP1‐Mediated SOX2 mRNA Stability in Endometrial Cancer
   Teng Xue et al, 2021, Advanced Science CrossRef
4. New frontiers against sorafenib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers
   Yu He et al, 2021, Pharmacological Research CrossRef
5. ERK Inhibitor Ulixertinib Inhibits High-Risk Neuroblastoma Growth In Vitro and In Vivo
   Yang Yu et al, 2022, Cancers CrossRef
6. Chemosensitization of non-small cell lung cancer to sorafenib via non-hydroxamate s-triazinedione-based MMP-9/10 inhibitors
   Hosam H. Khalil et al, 2024, Bioorganic Chemistry CrossRef
7. MiR‐92a mediates AZD6244 induced apoptosis and G1‐phase arrest of lymphoma cells by targeting Bim
   Xiao‐Bin Lv et al, 2014, Cell Biology International CrossRef
8. Morphoproteomics and biomedical analytics confirm the mTORC2/Akt pathway as a resistance signature and activated ERK and STAT3 as concomitant prosurvival/antiapoptotic pathways in metastatic renal cell carcinoma (RCC) progressing on rapalogs: Pathogenesis and therapeutic options
   Robert E. Brown et al, 2106, Oncotarget CrossRef
9. Anti-tumor innate immunity activated by intermittent metronomic cyclophosphamide treatment of 9L brain tumor xenografts is preserved by anti-angiogenic drugs that spare VEGF receptor 2
   Joshua C Doloff et al, 2014, Molecular Cancer CrossRef
10. Acquired resistance to combination treatment through loss of synergy with MEK and PI3K inhibitors in colorectal cancer
    Bhaskar Bhattacharya et al, 2016, Oncotarget CrossRef
11. Pan-RAF and MEK vertical inhibition enhances therapeutic response in non-V600 BRAF mutant cells
    Eszter Molnár et al, 2018, BMC Cancer CrossRef
12. Targeting ERK, an Achilles' Heel of the MAPK pathway, in cancer therapy
    Feifei Liu et al, 2018, Acta Pharmaceutica Sinica B CrossRef
13. The therapeutic value of SC66 in human renal cell carcinoma cells
    Ming Xu et al, 2020, Cell Death & Disease CrossRef
14. Protective Autophagy Attenuates the Cytotoxicity of MTI-31 in Renal Cancer Cells by Activating the ERK Pathway
    Yiwen Zang et al, 2024, Applied Biochemistry and Biotechnology CrossRef
15. Abrogation of STAT3 signaling cascade by zerumbone inhibits proliferation and induces apoptosis in renal cell carcinoma xenograft mouse model
    Muthu K. Shanmugam et al, 2015, Molecular Carcinogenesis CrossRef
16. Inhibition of the prolyl isomerase Pin1 enhances the ability of sorafenib to induce cell death and inhibit tumor growth in hepatocellular carcinoma
    Min Zheng et al, 2017, Oncotarget CrossRef
17. Methylglyoxal-Derived Advanced Glycation End Products (AGE4) Promote Cell Proliferation and Survival in Renal Cell Carcinoma Cells through the RAGE/Akt/ERK Signaling Pathways
    Han-Kyul Nam et al, 2021, Biological and Pharmaceutical Bulletin CrossRef
18. Synergistic chemotherapeutic effect of sorafenib-loaded pullulan-Dox conjugate nanoparticles against murine breast carcinoma
    Junhui Sui et al, 2017, Nanoscale CrossRef
19. Synergistic Effects of Lenvatinib (E7080) and MEK Inhibitors against Anaplastic Thyroid Cancer in Preclinical Models
    Keisuke Enomoto et al, 2021, Cancers CrossRef
20. The selective MEK1 inhibitor Selumetinib enhances the antitumor activity of everolimus against renal cell carcinoma in vitro and in vivo
    Yun Zou et al, 2017, Oncotarget CrossRef
21. MEK inhibitor effective against proliferation in breast cancer cell
    Yan Zhou et al, 2014, Tumor Biology CrossRef